FVIII and VWF production by purified human lung microvascular endothelial cells
Donor . | Passage (d)* . | FVIII, mU/mL . | Inhibition, %† . | VWF, mU/mL . |
|---|---|---|---|---|
| 5 | 1 (4) | 2.0 | > 95 | 0.4 |
| 6 | 1 (4) | < 1.5 | ND | < 0.1 |
| 7 | 2 (6) | 6.0 | > 95 | 16.0 |
| 5 | 2 (4) | 1.5 | ND | 9.4 |
| 5 | 2 (6) | 1.5 | ND | 18.1 |
| 6 | 2 (4) | 2.5 | > 95 | 15.3 |
| 6 | 2 (6) | 7.0 | > 95 | 23.7 |
Donor . | Passage (d)* . | FVIII, mU/mL . | Inhibition, %† . | VWF, mU/mL . |
|---|---|---|---|---|
| 5 | 1 (4) | 2.0 | > 95 | 0.4 |
| 6 | 1 (4) | < 1.5 | ND | < 0.1 |
| 7 | 2 (6) | 6.0 | > 95 | 16.0 |
| 5 | 2 (4) | 1.5 | ND | 9.4 |
| 5 | 2 (6) | 1.5 | ND | 18.1 |
| 6 | 2 (4) | 2.5 | > 95 | 15.3 |
| 6 | 2 (6) | 7.0 | > 95 | 23.7 |
ND indicates not done.
Passage number, with days after passage given in parentheses.
Cell-culture supernatant was mixed with the human monoclonal antibody BO2C11 and the residual FVIII activity measured after 15 minutes of incubation at room temperature. The results are expressed as the percentage inhibition of FVIII activity compared with samples incubated without antibody. The sensitivities of the FVIII and of the VWF assays were 1.5 mU/mL and 0.1 mU/mL, respectively.